Latest Equity Funding News

NOVONIX Limited reports progress scaling its Chattanooga synthetic graphite plant, secures major funding, and benefits from U.S. tariffs on Chinese imports, while narrowing its half-year loss.

Cynata Therapeutics has entered a five-year At-the-Market Subscription Agreement with Acuity Capital, enabling access to up to $7.5 million in standby equity capital with full discretion over timing and pricing.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Arafura Rare Earths has successfully raised approximately A$80 million through a two-tranche institutional placement and launched a A$5 million share purchase plan, strengthening its cash position ahead of the Nolans project final investment decision.

Magellan Financial Group reported a solid FY25 with an 8.2% rise in assets under management and a notable surge in strategic partnership income, offsetting a dip in investment management revenue.

Magellan Financial Group reported a 5% rise in operating profit for FY25 despite a 31% drop in statutory net profit, driven by strong growth in assets under management and booming income from strategic partnerships.

Lynch Group Holdings Limited reported solid revenue growth and a sharp reduction in net loss for FY2025, while announcing a scheme of arrangement acquisition by Hasfarm Holdings Limited.

Lynch Group Holdings has agreed to a $2.245 per share cash acquisition by Hasfarm, offering shareholders a 34.3% premium and securing board and major shareholder support. The scheme awaits shareholder and court approvals, with a final dividend declared ahead of completion.

MFF Capital Investments Limited posted a solid $432 million net profit for FY2025 despite a slight dip from last year, while raising its fully franked final dividend and completing the strategic acquisition of Montaka Global.

Universal Biosensors reported a 44% increase in net loss to A$10.45 million for H1 2025, alongside an 11% revenue decline, raising serious going concern doubts. The company is pursuing an A$8.5 million senior secured loan and equity raise to sustain operations.

Story-i Limited reported a significantly reduced half-year loss of $386,949 for December 2024, down from nearly $24 million a year earlier, as it exits its Indonesian operations and focuses on recapitalisation and new investments.

Pacific Lime and Cement Limited has approved the Final Investment Decision for its Central Lime Project, adopting a fully equity-funded approach that slashes upfront capital costs by 42% and secures strong backing from the Papua New Guinea government and local communities.